Bougainvillea: Wholly-owned subsidiary obtains the registration certificate for oxalic acid esomeprazole drops.

Announcement from Euphorbia pulcherrima: Its wholly-owned subsidiary, Guangzhou Euphorbia pulcherrima Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for oxalate escitalopram drops. The indication for oxalate escitalopram drops is for the treatment of depression and panic disorders with or without agoraphobia. The oxalate escitalopram drops approved by the company are classified as Category 3 chemical drugs for registration, considered equivalent through consistency evaluation. According to Minet data, the sales volume of escitalopram in Chinese urban and county public hospitals is estimated to be around 18.8 billion RMB in 2024.